{"entity":{"id":"nct03673501","kind":"trial","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","aka":[],"tldr":"A phase 3 trial of Ripretinib and Sunitinib in gastrointestinal stromal tumour, run by Deciphera Pharmaceuticals, LLC, active and no longer recruiting.","summary":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib is a phase 3 interventional study registered as NCT03673501 by Deciphera Pharmaceuticals, LLC, with 453 participants enrolled, started 2019-02-08 and due to reach its primary completion in 2021-09-01. Interventions recorded: Ripretinib and Sunitinib. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03673501","url":"https://clinicaltrials.gov/study/NCT03673501"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gist"],"sections":[],"technologies":[],"targets":[],"drugs":["ripretinib","sunitinib"],"companies":["deciphera"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03673501","phase":"3","setting":"A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib","sponsor":"Deciphera Pharmaceuticals, LLC","enrolled":453,"outcomes":[]},"route":"/trials/nct03673501/","neighbours":{"cancer":[{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"}],"drug":[{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"company":[{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/"}]}}